Carmenta Acquires Option to License Stanford Technology for Preeclampsia Test | GenomeWeb

NEW YORK (GenomeWeb News) – Maternal and fetal biotechnology firm Carmenta Bioscience today said it has acquired an option for a worldwide, exclusive license from Stanford University for technology aimed at diagnosing and predicting preeclampsia.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.